Haleon plc (NYSE:HLN) Short Interest Update

Haleon plc (NYSE:HLN) saw a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 7,910,000 shares, a drop of 22.8% from the October 15th total of 10,240,000 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 5,230,000 shares, the short-interest ratio is currently 1.5 days.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in HLN. Allspring Global Investments Holdings LLC acquired a new stake in Haleon in the 1st quarter worth approximately $43,000. Sei Investments Co. lifted its stake in shares of Haleon by 79.1% in the first quarter. Sei Investments Co. now owns 781,089 shares of the company’s stock worth $6,632,000 after buying an additional 345,036 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Haleon by 0.3% during the 1st quarter. Russell Investments Group Ltd. now owns 969,627 shares of the company’s stock worth $8,232,000 after buying an additional 3,072 shares during the period. Bleakley Financial Group LLC grew its stake in Haleon by 32.4% in the 1st quarter. Bleakley Financial Group LLC now owns 16,174 shares of the company’s stock valued at $137,000 after buying an additional 3,956 shares during the last quarter. Finally, Orion Portfolio Solutions LLC grew its stake in Haleon by 25.1% in the 1st quarter. Orion Portfolio Solutions LLC now owns 694,524 shares of the company’s stock valued at $5,897,000 after buying an additional 139,263 shares during the last quarter. 6.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on HLN shares. The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. Morgan Stanley raised their price target on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Berenberg Bank initiated coverage on Haleon in a report on Tuesday, August 6th. They set a “buy” rating for the company. Finally, UBS Group upgraded Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Haleon presently has a consensus rating of “Buy” and a consensus price target of $10.95.

Haleon Stock Up 0.9 %

NYSE HLN traded up $0.08 during trading on Friday, hitting $9.39. 8,494,420 shares of the company traded hands, compared to its average volume of 5,688,165. Haleon has a 12 month low of $7.89 and a 12 month high of $10.80. The business has a fifty day simple moving average of $10.10 and a 200 day simple moving average of $9.34. The company has a market capitalization of $42.51 billion, a P/E ratio of 27.62, a PEG ratio of 2.84 and a beta of 0.30. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.